Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia

Leuk Res. 2023 Sep:132:107357. doi: 10.1016/j.leukres.2023.107357. Epub 2023 Jul 20.

Authors

Christian K Hirt¹, Nandan Padmanabha¹, Phillip D Michaels²

Affiliations

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: pdmichaels@bwh.harvard.edu.

PMID: 37481994
DOI: 10.1016/j.leukres.2023.107357

No abstract available

Keywords: Acute myeloid leukemia; Cohesin; Myelodysplastic syndrome; Phylogeny; STAG2.

Publication types

Letter

MeSH terms

Cohesins
Core Binding Factor Alpha 2 Subunit / genetics
Core Binding Factor Alpha 2 Subunit / metabolism
DNA-Binding Proteins / genetics
Dioxygenases* / genetics
Humans
Leukemia, Myeloid, Acute* / genetics
Membrane Proteins / genetics
Mutation
Myeloproliferative Disorders* / genetics
Neoplasms*
Prognosis
Serine-Arginine Splicing Factors / genetics

Substances

Core Binding Factor Alpha 2 Subunit
SRSF2 protein, human
Serine-Arginine Splicing Factors
RUNX1 protein, human
TET2 protein, human
DNA-Binding Proteins
Dioxygenases
NRAS protein, human
Membrane Proteins